文献速递儿童保健预防保健、筛查与疫苗

BCG丹麦株与口服脊灰疫苗对印度低出生体重儿新生儿死亡率的影响:BLOW2多中心开放标签随机对照试验

Effect of BCG Danish and oral polio vaccine on neonatal mortality in newborn babies weighing less than 2000 g in India: multicentre open label randomised controlled trial (BLOW2).
PubMed 文献 · BMJ · 2025-09-22

在印度三家NICU开展的多中心开放标签随机对照试验,纳入5420例出生体重<2000g的新生儿,1:1随机分为早期接种组(入院48小时内接种BCG丹麦株0.1mL皮内注射加OPV)和对照组(延迟至出院时接种)。早期接种组全因新生儿死亡率为8.8%,对照组为10.1%,校正后风险比0.83(95%CI 0.69-0.98,P=0.03),感染相关死亡率亦降低(aHR 0.53,95%CI 0.40-0.70),未发生结核死亡及疫苗相关严重不良事件。

要点

  • 出生体重<2000g新生儿早期接种BCG-OPV可降低全因新生儿死亡率(aHR 0.83)。
  • 感染相关新生儿死亡率显著降低(aHR 0.53),提示非特异性保护效应。
  • 预防一例死亡需治疗人数为21(95%CI 10-245),无疫苗相关严重不良事件。

核心结论

  • 在体重<2000g的NICU新生儿中,中位日龄0.9天接种BCG丹麦株加OPV可降低全因新生儿死亡率,主要归因于非结核感染死亡减少的非特异性效应。

研究设计与样本

  • 多中心、开放标签、随机对照试验,在印度东南部三家三级NICU开展,7067例评估资格,5420例随机分组(2714例早期接种,2706例对照)。
  • 按NICU、性别和出生体重(<1000g、1000-1499g、1500-1999g)分层,中位入组日龄0.9天,中位出生体重1560g,9例失访。

主要发现

  • 早期接种组死亡238例(8.8%),对照组死亡273例(10.1%)。
  • 按人年计算的新生儿死亡率早期接种组为1.29、对照组为1.50,校正后风险比0.83(95%CI 0.69-0.98;P=0.03)。
  • 感染相关新生儿死亡率按人年计算早期接种组为0.40、对照组为0.73,校正后风险比0.53(95%CI 0.40-0.70)。
  • 预防一例死亡的需治疗人数为21(95%CI 10-245)。
  • 未发生结核死亡,未观察到与接种相关的严重不良事件。

关键数值与推荐

  • 纳入标准为出生体重<2000g的新生儿,干预为0.1mL BCG丹麦株皮内注射加OPV,早期组在入院48小时内接种,对照组延迟至出院时接种。

临床怎么用

  • 在高死亡率环境中,若由熟练接种人员对高比例新生儿在出生当天或出生后不久接种BCG-OPV,可能大幅降低新生儿死亡率。

局限性

  • 开放标签设计;感染相关死亡为主要次要结局且在试验进行三分之一时纳入;结果来自印度三家三级NICU,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To test the effect on all cause neonatal mortality (aged ≤28 days) of a dose of BCG Danish vaccine and oral polio vaccine (OPV) administered to newborn babies weighing <2000 g. DESIGN: Multicentre, open label, randomised controlled trial SETTING: Three tertiary neonatal intensive care units (NICUs) in southeast India. POPULATION: Newborn babies weighing <2000 g. 7067 were assessed for eligibility and 5420 were randomised (2714 BCG-OPV, 2706 control). INTERVENTIONS: Newborns were randomised 1:1 to receive 0.1 mL of BCG Danish intradermally plus OPV, either within 48 hours of admission to the NICU (early vaccination group) or delayed until at least the time of discharge (control group). Stratification was by NICU, sex, and birth weight (<1000 g, 1000-1499 g, 1500-1999 g). MAIN OUTCOME MEASURES: The primary outcome was all cause neonatal mortality. The main secondary outcome, included a third of the way through the trial, was neonatal mortality due to infection. RESULTS: Of the 5420 newborn babies randomised at a median age of 0.9 days and with a median birth weight of 1560 g, nine were lost to follow-up. Deaths occurred in 238 (8.8%) of 2714 newborn babies in the early vaccination group and 273 (10.1%) of 2706 in the control group. In intention-to-treat Cox survival analysis stratified by NICU and adjusted for postnatal age, birth weight, sex, and gestational age, neonatal mortality per person year was 1.29 in the early vaccination group and 1.50 in the control group (adjusted hazard ratio 0.83, 95% confidence interval (CI) 0.69 to 0.98; P=0.03). The number needed to treat to prevent one death was 21 (95% CI 10 to 245). Infection related neonatal mortality per person year was 0.40 in the early vaccination group and 0.73 in the control group (adjusted hazard ratio 0.53, 95% CI 0.40 to 0.70). No deaths from tuberculosis occurred, and no serious adverse effects were associated with vaccination. CONCLUSIONS: In newborn babies weighing <2000 g in intensive care, BCG-OPV administered at a median age of 0.9 days reduced all cause neonatal mortality owing to a decrease in deaths due to infections other than tuberculosis (a non-specific or off-target effect). A substantial reduction in neonatal mortality could be achieved if a skilled administrator vaccinated a high proportion of newborn babies in high mortality settings on the day of, or soon after, birth. TRIAL REGISTRATION: Clinical Trials Registry India CTRI/2017/01/007676.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Adhisivam B, Kamalarathnam C, Bhat BV, et al. Effect of BCG Danish and oral polio vaccine on neonatal mortality in newborn babies weighing less than 2000 g in India: multicentre open label randomised controlled trial (BLOW2). BMJ. 2025. PMID: 40983468. doi:10.1136/bmj-2025-084745

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。